Physician profile
Sami Ismail
NPI 1033670385
$3,847.74
in general payments reported to CMS, 2019-2025
21 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $775 · 2024: $1,420 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $816.67 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $797.60 | 2023-2025 | |
| Novo Nordisk INC | $394.98 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $305.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $279.45 | 2023-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.07 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $202.00 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $185.61 | 2022-2025 | Zepbound, Mounjaro |
| Almatica Pharma LLC | $151.67 | 2023-2025 | Loreev Xr, Gralise |
| Bayer Healthcare Pharmaceuticals INC. | $95.16 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $58.02 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $55.66 | 2024-2025 | |
| Glaxosmithkline, LLC. | $49.31 | 2023 | Shingrix, Rotarix, Bexsero |
| Idorsia Pharmaceuticals US INC | $37.04 | 2023-2024 | Quviviq |
| Edwards Lifesciences Corporation | $33.74 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $29.60 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $25.75 | 2022 | |
| Corcept Therapeutics | $22.54 | 2023 | Korlym |
| Antares Pharma, INC. | $15.11 | 2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2023 | Seglentis |
| Sumitomo Pharma America, INC. | $11.58 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.